Determination of Pharmacokinetics of Different Curcuminoids Preparations: Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Amman, Jordan
- the university of Jordan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Male and female Apparently healthy adults
Exclusion Criteria:
Postmenopausal women Smokers Overweight Chronic diseases
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Curcumin H2O SAP
Water soluble version of turmeric extract standardized to 10% curcuminoids will be administered orally (1 dose)
|
water soluble version of turmeric extract standardized to 10% curcuminoids .
Other Names:
|
|
Active Comparator: Tumeric with piperine SAP
Turmeric extract standardized to 95% curcuminoids in combination with 5 mg of piperine per capsule will be administered orally (1 dose)
|
water soluble version of turmeric extract standardized to 10% curcuminoids .
Other Names:
|
|
Placebo Comparator: Tumeric without piperine
Turmeric extract standardized to 95% curcuminoids without piperine will be administered orally (1 dose)
|
water soluble version of turmeric extract standardized to 10% curcuminoids .
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood concentration of bisdemethoxycurcumin
Time Frame: [Time Frame: Change during 8 hours]
|
plasma bisdemethoxycurcumin levels using LC MS/MS
|
[Time Frame: Change during 8 hours]
|
|
Blood concentration of desmethoxycurcumin
Time Frame: [Time Frame: Change during 8 hours]
|
plasma desmethoxycurcumin levels using LC MS/MS
|
[Time Frame: Change during 8 hours]
|
|
Blood concentration of piperine-curcuminoids
Time Frame: [Time Frame: Change during 8 hours]
|
plasma piperine-curcuminoids levels using LC MS/MS
|
[Time Frame: Change during 8 hours]
|
|
Blood concentration of hexahydrocurcumin
Time Frame: [Time Frame: Change during 8 hours]
|
plasma hexahydrocurcumin levels using LC MS/MS
|
[Time Frame: Change during 8 hours]
|
|
Blood concentration of curcumin diethyl disuccinate
Time Frame: [Time Frame: Change during 8 hours]
|
plasma curcumin diethyl disuccinate levels using LC MS/MS
|
[Time Frame: Change during 8 hours]
|
|
Blood concentration of tetrahydrocurcumin
Time Frame: [Time Frame: Change during 8 hours]
|
plasma tetrahydrocurcumin levels using LC MS/MS
|
[Time Frame: Change during 8 hours]
|
|
Blood concentration of curcumin
Time Frame: [Time Frame: Change during 8 hours]
|
plasma curcumin levels using LC MS/MS
|
[Time Frame: Change during 8 hours]
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL Jr, Brenner DE. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila). 2011 Mar;4(3):354-64. doi: 10.1158/1940-6207.CAPR-10-0098. Erratum In: Cancer Prev Res (Phila). 2012 Dec;5(12):1407. Dosage error in article text.
- Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008 Jul 15;14(14):4491-9. doi: 10.1158/1078-0432.CCR-08-0024.
- Sahebkar A, Henrotin Y. Analgesic Efficacy and Safety of Curcuminoids in Clinical Practice: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pain Med. 2016 Jun;17(6):1192-202. doi: 10.1093/pm/pnv024. Epub 2015 Dec 14.
- Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res. 2014 Mar;58(3):516-27. doi: 10.1002/mnfr.201300724. Epub 2014 Jan 9. Erratum In: Mol Nutr Food Res. 2014 Mar;58(3):647. Dosage error in article text.
- Kocher A, Bohnert L, Schiborr C, Frank J. Highly bioavailable micellar curcuminoids accumulate in blood, are safe and do not reduce blood lipids and inflammation markers in moderately hyperlipidemic individuals. Mol Nutr Food Res. 2016 Jul;60(7):1555-63. doi: 10.1002/mnfr.201501034. Epub 2016 May 23.
- Fanca-Berthon P, Tenon M, Bouter-Banon SL, Manfre A, Maudet C, Dion A, Chevallier H, Laval J, van Breemen RB. Pharmacokinetics of a Single Dose of Turmeric Curcuminoids Depends on Formulation: Results of a Human Crossover Study. J Nutr. 2021 Jul 1;151(7):1802-1816. doi: 10.1093/jn/nxab087.
- Kocher A, Schiborr C, Behnam D, Frank J: The oral bioavailability of curcuminoids in healthy humans is markedly enhanced by micellar solubilisation but not further improved by simultaneous ingestion of sesamin, ferulic acid, naringenin and xanthohumol.Journal of functional foods 2015, 14:183-191.
- Baum L, Cheung SK, Mok VC, Lam LC, Leung VP, Hui E, Ng CC, Chow M, Ho PC, Lam S, Woo J, Chiu HF, Goggins W, Zee B, Wong A, Mok H, Cheng WK, Fong C, Lee JS, Chan MH, Szeto SS, Lui VW, Tsoh J, Kwok TC, Chan IH, Lam CW. Curcumin effects on blood lipid profile in a 6-month human study. Pharmacol Res. 2007 Dec;56(6):509-14. doi: 10.1016/j.phrs.2007.09.013. Epub 2007 Sep 18.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Curcumin
Other Study ID Numbers
Other Study ID Numbers
- 10-2022/13342
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.